UNITED MITOCCHONDRIAL DISEASE FOUNDATION

HOPE. ENERGY. LIFE.

ANNUAL REPORT

July 1, 2010 - June 30, 2011

• Mitochondrial Disease Affects Children and Adults •
The United Mitochondrial Disease Foundation is bringing hope, energy, and life to individuals and families affected by mitochondrial disease.
2010 - 2011 Annual Report

Contents

About the Foundation ........................................... 4
Chairman’s Message ........................................... 5
Executive Director’s Message .............................. 6
UMDF Accomplishments for July 1, 2010 - June 30, 2011 7
Research Grant Program & Results ...................... 8
2011 Research Grant Award Recipients ................ 9
Financial Stewardship - How Each Dollar is Spent .... 10
Grant Funding by Year through 2011 .................. 11
UMDF Financial Statements & Independent Auditor’s Report 12
UMDF National Office Staff .................................. 26
UMDF Scientific and Medical Advisory Board .......... 27
UMDF Board of Trustees ................................... 28
UMDF Chapters, Groups, and Ambassadors ........... 30

On the cover:
Savannah Greenawalt and Dr. Heather Baudet smile at one another at the Energy for Life Walkathon that was held in Charlotte, North Carolina on October 15, 2011. Both of them have mitochondrial disease.
About the Foundation...

In June of 2011, the United Mitochondrial Disease Foundation (UMDF) celebrated 15 years. The UMDF was founded by Charles A. Mohan, Jr. and his wife, Adrienne in 1996 through the merger of several smaller foundations established by those who lost loved ones to the disease. Starting as a volunteer organization located in a basement, the UMDF has grown into an internationally recognized non-profit organization. The UMDF staff responds to hundreds of inquiries each month about mitochondrial diseases and offers affected individuals and families information, resources, support, and referrals to experts in the mitochondrial field. The UMDF is represented nationally around the world by more than 60 chapters, groups, and ambassadors.

UMDF Mission
The UMDF mission is to promote research and education for the diagnosis, treatment and cure of mitochondrial disorders and to provide support to affected individuals and families. The UMDF is committed to increasing funding for mitochondrial disease research – to alleviate the suffering of thousands who have this debilitating, incurable, and often fatal disease and to develop a better understanding of the treatments for the many common illnesses and chronic conditions associated with it.

Research
Understanding mitochondrial disease has the potential to open a new world of knowledge, transforming medicine and cutting across all medical disciplines to uncover better treatments for a range of serious diseases. The UMDF has already achieved tremendous success in marshalling resources for new research and improving awareness and understanding of mitochondrial disease. Since its inception, the foundation has funded more than $8 million in research, making it the leading non-governmental contributor of grants focused solely on mitochondrial disease. This research has lead to a range of invaluable new breakthroughs. To learn more about UMDF research efforts, visit: www.umdf.org.

Family Support
The UMDF creates caring, supportive communities across the nation for adults, children and families suffering from mitochondrial disease through more than 60 local chapters, groups, and ambassadors. This allows UMDF members to network with other families and individuals and to talk about how to live with mitochondrial disease.

Information and Communication
The UMDF is committed to answering patients’, policymakers’ and the medical community’s questions about mitochondrial disease – including important details about diagnosis, wide-ranging symptoms, and existing treatment.

Each year, the UMDF hosts the largest international research symposium dedicated to mitochondrial disease where the world’s leading researchers meet with doctors, patients, and their families to exchange valuable knowledge. The UMDF also strives to build awareness of mitochondrial disease among physicians and healthcare providers by bringing the world’s experts to them through its “Grand Rounds Program.”

The UMDF advocates on the national level and empowers members to advocate on the local level regarding issues of medical funding and children’s health issues, as well as social services for the medically fragile and disabled. In addition, the UMDF provides information about fundraisers and educational programs and maintains a website to provide the latest news and information about issues relating to mitochondrial disease research. The UMDF also publishes a quarterly newsletter that includes medical, advocacy, and support information.
Chairman’s Message

This annual report will highlight one of the things that I am most proud of. For every dollar raised for the UMDF, $.81 is used for programming. That means that 81% of our annual budget is spent on such items as research, education, support, and advocacy.

As this report highlights, in FY 2011, the Board of Trustees increased funding over FY 2010 levels by 50%. While our Finance Committee remained concerned about the economy, they were confident that our Energy for Life Walkathons, introduced in FY 2009/2010, would provide the financial resources that allowed us to increase our commitment to funding the research that our scientific and medical experts believe can bring us closer to better cures and treatments. The increase in research grant expenditures allowed the UMDF Grant Review Committee to fund five grants this fiscal year. At our annual symposium in 2011, I made a commitment that, barring any unforeseen downturn in the economy or the financial health of the UMDF, we would bring research grant funding back to the million dollar level.

I would also like to point out that thanks to a generous donation and a targeted development initiative, the UMDF was able to fund our first ever Clinical Fellowship. Anna-Kaisa Niemi, MD, PhD was the recipient of this two-year fellowship. This is a program that we want to continue. We believe that in funding this program to further educate those interested in mitochondrial medicine, we may be funding an individual who may discover a cure in the future.

One of the highlights in this past fiscal year was the first ever gathering between patients, families, and the scientific community for a session on clinical trials at our annual symposium. The information presented and shared is critical if we are to ever get to a cure. There is really no way to test the efficacy of many of the potential treatments that are currently in the pipeline and those still in planning without clinical trials.

Our programming budget also contains funding for all of the programs that are important to affected individuals and families – support, education, and advocacy. Aside from our one-of-a-kind symposium, I am proud to say that UMDF has provided 77 family support meetings and opportunities for patients and the medical community to interact; more than any other mitochondrial disease related organization. Some of these meetings included the attendance of medical experts who were brought to locations around the country to answer your questions and provide you with the latest information and potential treatments. In all, more than 4,000 people attended these information sessions. We also educated physicians, clinicians, and scientists by providing 19 Grand Rounds Programs across the United States. These programs are critical because they allow our experts in mitochondrial medicine to travel to hospitals in your communities and educate doctors, nurses, and other caregivers about mitochondrial diseases and the latest information available.

These programming funds are also used on Capitol Hill. While we know that our measures in the House and Senate did not get introduced in 2010, the fruits of your hard work in contacting your elected officials have paid off. As a direct result of our legislation, The National Institutes of Health (NIH) began a dialogue with the UMDF and our Scientific and Medical Advisory Board about ways that items we ask for in the bill could be implemented. These very successful meetings with the NIH are expected to produce a workshop at the NIH focusing on primary mitochondrial disease and ways to better collaborate regarding research. We are very excited about this; however, none of this would have happened without your help and the help of Senator Barbara Boxer (D-CA) and Rep. Jim McDermott (D-WA). We continue to work to have language calling for more research dollars inserted into the budget proposed to President Obama and within the research budgets at the Department of Defense.

I am also very proud to tell you that the UMDF remains below the national averages when it comes to expenditures. Fundraising expenses continue to decline with the implementation of our Energy for Life Walkathons across the nation. And, our administrative costs remain very low at 6% of budget.

As we move forward, the UMDF continues to position itself as the leader in research, education, and support for our community. We welcome the future; I can assure you that the UMDF will continue to rise to the challenges presented in the ever-changing world of mitochondrial medicine.
Executive Director’s Message

William James, U.S. pragmatist philosopher and psychologist, said, “The great use of life is to spend it for something that outlasts it.”

UMDF continues to strategically plan for the future, and with the support and guidance of the board of trustees, our members and supporters, is building a foundation that will continue to grow and move forward as we continue our quest toward treatments and cures for mitochondrial diseases.

Early in 1997, the young and fledgling UMDF recognized the lack of a support network for families suffering with mitochondrial disease. We realized then that we were in a unique position to have a positive impact on our Mito community. August 1, 1998, the first UMDF Support Group, Delaware Valley Support Group at Children’s Hospital in Philadelphia, was formed.

From that first support group, UMDF grew to what is now the largest patient support network for mitochondrial disease in the world, represented by over 85 groups across the country, and is now being organized into geographic regions. The first pilot region, consisting of North and South Carolina, Tennessee, Georgia, Alabama and Florida, is being led by UMDF’s new Regional Coordinator, Margaret Moore, who resides in Charlotte, NC.

Already, under this new structure, family support meetings have doubled, as have the requests for hospital grand rounds. UMDF continues to grow its speakers’ bureau, enabling us to bring mitochondrial specialists to you. Plans are also being developed for mini-symposia in various states within the new region, and plans are also developing for the next region and regional coordinator.

UMDF represents the U.S. as a founding member of the International Mito Patients (IMP). This group, with representatives from Germany, Spain, France, Belgium, Italy and The Netherlands, will bring a global approach to connecting clinicians, researchers, and research and patients, and enhance communications and world-wide collaboration.

It was in 1997 that UMDF funded its first grant in the amount of $30,000. Thirteen years and $8 million later, we are the largest non-governmental funder of primary mitochondrial disease research in the world. This current grant cycle has the UMDF Grant Review Committee reviewing 44 submitted research proposals.

Successful political advocacy has created a heightened awareness among members of Congress which has spurred much needed discussion with many of the NIH Institutes. These discussions have resulted in the first NIH/UMDF Workshop on mitochondrial dysfunction. On March 8 and 9, 2012, UMDF organized and participated with 85 NIH intramural and extramural researchers to investigate and discuss the following goals: (1) share information related to primary mitochondrial disease among the NIH Intramural and Extramural Research Program Investigators, (2) develop and/or enhance systems to facilitate future collaboration and sharing of information, (3) survey obstacles, needs and priorities of primary mitochondrial diseases research, and (4) develop mechanisms to enhance translation of basic science discoveries to diagnostics and therapeutics. The results of this unprecedented workshop will be discussed at the June 2012 UMDF Symposium in Washington D.C.

Due to a generous grant from the Rembrandt Foundation, UMDF was able to fund its first Clinical Fellow in 2011. The UMDF clinical fellowship award is a one or two year award designed to support the training of a physician scientist who plans to practice clinical management of patients with mitochondrial disorders AND to conduct clinically (patient) oriented research in the field of mitochondrial medicine. The purpose of the award is to expand the number of clinicians and physician scientists practicing clinical management of patients with mitochondrial disorders and conducting clinically (patient) oriented research in the field of mitochondrial medicine. This year’s recipient is Anna-Kaisa Niemi MD, PhD, from Stanford University, who will be working with Mito specialist, Dr. Greg Enns.

The North American Mitochondrial Disease Consortium (NAMDC) is one of 19 NIH funded consortia. The UMDF continues to support NAMDC as its patient advocacy member, along with their 13 clinical sites. NAMDC sites will be featured at the June 2012 UMDF Symposium and will be taking samples and enrolling patients into the NAMDC Patient Registry.

With your support, UMDF has come a long way; and with your continued support, UMDF will stay focused on its mission: “PROMOTING RESEARCH AND EDUCATION FOR THE DIAGNOSIS, TREATMENT AND CURE OF MITOCHONDRIAL DISORDERS AND PROVIDING SUPPORT TO AFFECTED INDIVIDUALS AND FAMILIES.”

With your help, this is what we do every day; this is the reason we are here!
**UMDF Accomplishments for July 1, 2010 - June 30, 2011**

**September 2010**
More than 5,000 pieces of collateral were shipped from the UMDF national office to members around the nation as Awareness Week was celebrated. Seven Energy for Life Walkathons were held around the country raising $331,841.

**October 2010**
UMDF’s Grand Rounds Program held its 43rd meeting designed in a hospital setting to educate physicians about mitochondrial disease. Our Grand Rounds Program focuses on basic information, what symptoms physicians should look for, and how to treat affected patients.

**December 2010**
As a result of a workshop conducted by the National Institute of Environmental Health Sciences (NIEHS) and supported by the UMDF at a previous symposium, the NIEHS announced that it will provide $2.5 million in this fiscal year to fund 6-8 grants for approved projects. The workshop was designed to explore the state of science and technology with experts in the field of mitochondrial physiology and function with the goal of developing biomarkers of mitochondrial dysfunction related to genetics and environmental exposures.

**January 2011**
The North American Mitochondrial Disease Consortium began enrolling affected individuals in its patient contact registry. UMDF serves as the liaison between NAMDC and the mitochondrial disease patient community.

**February 2011**
UMDF met with representatives of the National Institutes of Health (NIH) in the Office of U.S. Senator Barbara Boxer. NIH outlined current research into mitochondrial medicine and is seeking ways to help further research and collaboration among the institutes.

**March 2011**
UMDF held its 55th Patient and Family Support meeting for the fiscal year. During FY 2010/2011, the UMDF offered support and education to more than 4,100 people over the course of the year.

**April 2011**
The UMDF learned that the United States House of Representatives has included language in an appropriations bill that calls for additional research spending for mitochondrial diseases. The inclusion of this language comes after multiple visits to Capitol Hill by UMDF staff and board members.

**May 2011**
The NIH met with the UMDF in Bethesda, MD. The goal of the meeting was to define ways that the NIH and UMDF could work together to define research that is needed in mitochondrial medicine and to find ways that current researchers can collaborate across the NIH and externally. The outcome of the meeting was the idea of holding a workshop on the NIH campus later in 2011 or 2012. All 28 institutes at NIH were represented, as well as members of the UMDF’s Board of Trustees and Scientific and Medical Advisory Board.

**June 2011**
UMDF celebrated its 15th anniversary by awarding $500,000 in research grants and funding its first ever clinical fellowship at its annual Mitochondrial Medicine Symposium in Chicago, IL.

UMDF, for the first time ever, held a combined scientific and family session at its symposium to provide information on clinical trials. The session attracted media coverage in the Chicago Tribune and Los Angeles Times.

In conjunction with Edison Pharmaceuticals, the UMDF held a special seminar during the symposium for patients and clinicians interested in EPI -743. (EPI-743 is an Orphan Drug that is administered to subjects diagnosed with genetically confirmed inherited respiratory chain disease of the mitochondria that were either at end-of-life or at risk of blindness.)
UMDF Awarded $500,000 in Research Towards a Cure for Mitochondrial Disease in 2011

Research Grants were awarded June 17, 2011 at the UMDF Annual Symposium in Chicago, IL

The United Mitochondrial Disease Foundation (UMDF) awarded a half of a million dollars to five researchers whose projects may lead to a cure for mitochondrial disease or better treatments for those who battle it. The research grant awards were presented at the UMDF’s annual symposium, “Mitochondrial Medicine 2011: Chicago” which was held at the Renaissance Schaumburg Convention Center Hotel in Schaumburg, IL. This year’s awards bring the total of amount of UMDF funded research to nearly $8 million since 1996. The UMDF is the largest, non-governmental contributor of grants focused on mitochondrial disease research.

In 2011, the UMDF received 119 letters of inquiry from the scientific and medical community seeking funding for their proposed research projects. The UMDF Grant Review Committee asked 31 of the projects that were submitted for full proposals. The Grant Review Committee selected the top five proposals that they felt could provide the most promising research towards the diagnosis, treatment, and ultimate cure of mitochondrial disease.

Charles A. Mohan, Jr., UMDF Chief Executive Officer/Executive Director said, “We are pleased that we can provide this much money towards research that will hopefully lead to a cure for mitochondrial disease. It is truly our mission to support those affected by this devastating disease and find a cure for it.”

A summary of the recipients, a brief description of their projects, and the award amounts are as follows.

2011 Research Grant Award Recipients

**Chairman’s Award - $120,000 for 2 yrs.**
Brett Kaufman, PhD
Department of Animal Biology University of Pennsylvania, Philadelphia, PA
“Regulatory mechanisms governing TFAM-mediated mtDNA copy number control”
His research could lead to therapies that would increase the number of copies of normal mitochondrial DNA in patients with specific types of mitochondrial disease.

**Chairman’s Award - $120,000 for 2 yrs.**
Nicola Brunetti-Pierri, MD
Telethon Institute of Genetics and Medicine
Fondazione Telethon, Rome, Italy
“Therapeutic Interventions for Pyruvate Dehydrogenase Deficiency.”
He is seeking safe and effective treatments for a genetic condition that causes deficiencies of an important enzyme in the energy pathway of mitochondria.
2011 Research Grant Award Recipients

Grant Award $100,000 for 2 yrs.
Miguel Garcia-Diaz, PhD
Department of Pharmacological Sciences
Stony Brook University, Stony Brook, NY
“Deficiencies of tRNA maturation and the pathogenesis of mitochondrial diseases.”
He will study the regulation of mitochondrial transfer RNAs, molecules that are intrinsic to synthesis of the energy metabolism enzymes in mitochondria.

Grant Award $80,000 for 2 yrs.
Ying Dai, MD, PhD
Department of Neurology
Beth Israel Deaconess Medical Center, Boston, MA
“Driving Selection Against Heteroplasmic Mitochondrial DNA Mutations by Enhancing Mitophagy.” He hopes to develop a mechanism whereby mitochondria with abnormal mutated mitochondrial DNA will be eliminated from cells, with the goal of restoring normal function.

Grant Award $80,000 for 2 yrs.
Katie Clark, PhD
Department of Zoology, Oregon State University, Corvallis, OR
“Identifying genes that prevent mitochondrial DNA deletions: a high-throughput approach using Caenorhabditis elegans.” Her research will provide insight into the mechanisms responsible for mitochondrial DNA deletion, a major cause of mitochondrial disease.

First Clinical Fellowship Training Award

The United Mitochondrial Disease Foundation is proud to announce a new Clinical Fellowship Program funded through generous donations from UMDF supporters. The $75,000 award is for one year. It is given to a physician scientist who will practice clinical management of patients and who will conduct patient-oriented research in the field of mitochondrial medicine. The recipient of the 2011 award is Anna-Kaisa Niemi, MD, PhD from the Stanford University Medical Center.

“This program is designed to support the training of physician scientists who plan to train in the field of mitochondrial medicine,” said Charles A. Mohan, Jr., CEO and Executive Director, while making the award at the UMDF’s 2011 Symposium in Chicago. “We must encourage physicians and scientists to enter this field as we all recognize that there is a tremendous need for more physicians and scientists in the field.”
2011 Allocations of Each Dollar Raised

UMDF MAXIMIZES THE POWER OF EVERY DOLLAR DONATED

For every dollar donated to the UMDF over the last five years, $.81 is allocated to research, education, and awareness; $.13 is allocated to fundraising and $.06 is allocated to administrative expenses.

This chart shows the allocation of funds for every dollar donated to the UMDF.

**Research** - .37 cents from every dollar donated is used for the UMDF Research Grant Program to fund the most promising research.

**Education** - .32 cents from every dollar donated is used for programs that benefit patients, families, and the medical community. These programs include our annual Symposium, the UMDF Grand Rounds and Family Meeting Programs, our educational materials (Mito 101 and the MitoFirst Handbook) and our support of newly diagnosed and current patients.

**Awareness/Advocacy** - .12 of every dollar is used to promote awareness of mitochondrial disease as well as support our advocacy efforts that are designed to secure additional funding for primary mitochondrial disease research.

**Fundraising** - .13 cents of every dollar is allocated towards fundraising. It should be noted that the entire “Energy for Life” training program was the result of a generous gift – so no donor dollars were used.

**Administrative** - .06 cents of every dollar is allocated to rent, utilities, UMDF operational costs.
Since 1996, the UMDF has funded more than $8 million in research projects aimed at providing patients with a faster diagnosis and better treatment options. Our ultimate objective is to find a cure for mitochondrial disease.

For a complete listing our funded research projects, visit www.umdf.org/fundedprojects.
UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.

FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2011 AND 2010 AND INDEPENDENT AUDITOR’S REPORT

* * * * * *

TABLE OF CONTENTS

| Page |
|------------------------|------------------|
| Independent Auditor’s Report ............................................................... | 13 |
| Financial Statements |
| Statements of Financial Position .............................................................. | 14 |
| Statements of Activities and Changes in Net Assets ................................ | 15 |
| Statements of Functional Expenses .......................................................... | 16 |
| Statements of Cash Flows ........................................................................... | 17 |
| Notes to Financial Statements ................................................................... | 18 |
INDEPENDENT AUDITOR’S REPORT

To the Board of Trustees of the
United Mitochondrial Disease Foundation, Inc.

We have audited the accompanying statements of financial position of the United Mitochondrial Disease Foundation, Inc. (“the Foundation”) as of June 30, 2011 and 2010, and the related statements of activities, functional expenses and cash flows for the years then ended. These financial statements are the responsibility of the Foundation’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the United Mitochondrial Disease Foundation, Inc. as of June 30, 2011 and 2010, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

STEL Mack DOBRANSKY & EANNACE, LLC
McMurray, Pennsylvania

January 6, 2012
# UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.

## STATEMENTS OF FINANCIAL POSITION

**JUNE 30, 2011 AND 2010**

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 564,165</td>
<td>$ 368,726</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>16,900</td>
<td>22,987</td>
</tr>
<tr>
<td>Inventories</td>
<td>25,811</td>
<td>33,894</td>
</tr>
<tr>
<td>Investments (Note 3)</td>
<td>1,386,772</td>
<td>1,144,449</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>15,773</td>
<td>28,597</td>
</tr>
<tr>
<td>Fixed assets - net (Note 4)</td>
<td>40,132</td>
<td>63,171</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$ 2,049,553</td>
<td>$1,661,824</td>
</tr>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$ 207,854</td>
<td>$ 213,936</td>
</tr>
<tr>
<td>Accrued liabilities</td>
<td>37,539</td>
<td>53,088</td>
</tr>
<tr>
<td>Grants payable (Note 5)</td>
<td>849,469</td>
<td>774,169</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>38,765</td>
<td>148,846</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>1,133,627</td>
<td>1,190,039</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>593,399</td>
<td>204,176</td>
</tr>
<tr>
<td>Temporarily restricted (Note 7)</td>
<td>322,527</td>
<td>267,609</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>915,926</td>
<td>471,785</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td>$ 2,049,553</td>
<td>$1,661,824</td>
</tr>
</tbody>
</table>

See Independent Auditor’s Report and Notes to the Financial Statements
UNITED MITOCHONDRIAL
DISEASE FOUNDATION, INC.
STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Temporarily Unrestricted</td>
<td>Temporarily Restricted</td>
</tr>
<tr>
<td><strong>PUBLIC SUPPORT AND REVENUE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fundraising</td>
<td>$1,469,512</td>
<td>$ 144,870</td>
</tr>
<tr>
<td>Contributions</td>
<td>199,680</td>
<td>172,057</td>
</tr>
<tr>
<td>In honor of</td>
<td>127,879</td>
<td>0</td>
</tr>
<tr>
<td>In memory of</td>
<td>83,623</td>
<td>0</td>
</tr>
<tr>
<td>In kind</td>
<td>33,605</td>
<td>0</td>
</tr>
<tr>
<td>Grants</td>
<td>57,214</td>
<td>178,167</td>
</tr>
<tr>
<td>Cancellation of grants payable</td>
<td>43,501</td>
<td>0</td>
</tr>
<tr>
<td>Total support</td>
<td>2,015,014</td>
<td>495,094</td>
</tr>
<tr>
<td>Revenue:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symposium and seminars</td>
<td>219,625</td>
<td>2,000</td>
</tr>
<tr>
<td>Membership</td>
<td>21,161</td>
<td>0</td>
</tr>
<tr>
<td>Sales</td>
<td>11,214</td>
<td>0</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total revenue</td>
<td>252,000</td>
<td>2,000</td>
</tr>
<tr>
<td>Investment income</td>
<td>38,760</td>
<td>0</td>
</tr>
<tr>
<td>Net unrealized gain on investments</td>
<td>204,017</td>
<td>0</td>
</tr>
<tr>
<td>Net realized gain (loss) on investments</td>
<td>(120)</td>
<td>0</td>
</tr>
<tr>
<td>Net assets released from program restrictions</td>
<td>442,176</td>
<td>(442,176)</td>
</tr>
<tr>
<td>Total support and revenue</td>
<td>2,951,847</td>
<td>54,918</td>
</tr>
<tr>
<td><strong>FUNCTIONAL EXPENSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>748,459</td>
<td>0</td>
</tr>
<tr>
<td>Public awareness</td>
<td>242,315</td>
<td>0</td>
</tr>
<tr>
<td>Education/member support</td>
<td>830,930</td>
<td>0</td>
</tr>
<tr>
<td>Total program services</td>
<td>1,821,704</td>
<td>0</td>
</tr>
<tr>
<td>Supporting services:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administrative and general</td>
<td>130,923</td>
<td>0</td>
</tr>
<tr>
<td>Fundraising</td>
<td>609,997</td>
<td>0</td>
</tr>
<tr>
<td>Total supporting services</td>
<td>740,920</td>
<td>0</td>
</tr>
<tr>
<td>Total expenses</td>
<td>2,562,624</td>
<td>0</td>
</tr>
<tr>
<td><strong>CHANGES IN NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NET ASSETS - Beginning of year</td>
<td>389,223</td>
<td>54,918</td>
</tr>
<tr>
<td>NET ASSETS - End of year</td>
<td>204,176</td>
<td>267,609</td>
</tr>
<tr>
<td>Total</td>
<td>$ 593,399</td>
<td>$ 322,527</td>
</tr>
</tbody>
</table>

See Independent Auditor's Report and Notes to the Financial Statements
## Statements of Functional Expenses

**For the Years Ended June 30, 2011 and 2010**

<table>
<thead>
<tr>
<th></th>
<th>2011 Total</th>
<th>Program Services</th>
<th>Supporting Services</th>
<th>2010 Total</th>
<th>Program Services</th>
<th>Supporting Services</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Research</td>
<td>Public Awareness</td>
<td>Education Member Support</td>
<td>Admin. &amp; General</td>
<td>Fundraising</td>
<td>Research</td>
</tr>
<tr>
<td>Bad debt expense</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td>Bank fees</td>
<td>$0</td>
<td>$0</td>
<td>$2,443</td>
<td>$6,796</td>
<td>$8,361</td>
<td>$17,600</td>
</tr>
<tr>
<td>Chapter support</td>
<td>$503</td>
<td>$49,082</td>
<td>$0</td>
<td>$1,666</td>
<td>$51,251</td>
<td>$769</td>
</tr>
<tr>
<td>Depreciation</td>
<td>$2,312</td>
<td>$16,036</td>
<td>$4,159</td>
<td>$7,018</td>
<td>$34,186</td>
<td>$4,382</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$68</td>
<td>$5,378</td>
<td>$230,877</td>
<td>$0</td>
<td>$6,477</td>
<td>$4,604</td>
</tr>
<tr>
<td>Total functional expenses</td>
<td>$748,459</td>
<td>$242,315</td>
<td>$830,930</td>
<td>$130,923</td>
<td>$609,997</td>
<td>$2,562,624</td>
</tr>
</tbody>
</table>

See Independent Auditor’s Report and Notes to the Financial Statements
# UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.

## STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$ 444,141</td>
<td>$(23,111)</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets provided by (used in) operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>34,186</td>
<td>59,071</td>
</tr>
<tr>
<td>Realized (gain) loss on sale of investments</td>
<td>120</td>
<td>(924)</td>
</tr>
<tr>
<td>Unrealized (gain) on investment</td>
<td>(204,017)</td>
<td>(94,550)</td>
</tr>
<tr>
<td>Changes in assets (increase)/decrease:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contribution receivable</td>
<td>0</td>
<td>10,000</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>6,087</td>
<td>(9,055)</td>
</tr>
<tr>
<td>Inventories</td>
<td>8,083</td>
<td>(6,952)</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>12,824</td>
<td>747</td>
</tr>
<tr>
<td>Changes in liabilities (decrease)/increase:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>(6,082)</td>
<td>(9,259)</td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>(15,549)</td>
<td>20,177</td>
</tr>
<tr>
<td>Grants payable</td>
<td>75,300</td>
<td>(248,908)</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(110,081)</td>
<td>23,517</td>
</tr>
<tr>
<td>Net cash provided by (used in) operating activities</td>
<td>245,012</td>
<td>(279,247)</td>
</tr>
<tr>
<td><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of equipment</td>
<td>(11,147)</td>
<td>(21,345)</td>
</tr>
<tr>
<td>Purchase of investments</td>
<td>(43,330)</td>
<td>(58,351)</td>
</tr>
<tr>
<td>Proceeds on sale of investments</td>
<td>4,904</td>
<td>32,980</td>
</tr>
<tr>
<td>Net cash provided by (used in) investing activities</td>
<td>(49,573)</td>
<td>(46,716)</td>
</tr>
<tr>
<td><strong>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</strong></td>
<td>195,439</td>
<td>(325,963)</td>
</tr>
<tr>
<td><strong>CASH AND CASH EQUIVALENTS – Beginning of year</strong></td>
<td>368,726</td>
<td>694,689</td>
</tr>
<tr>
<td><strong>CASH AND CASH EQUIVALENTS – End of year</strong></td>
<td>$ 564,165</td>
<td>$ 368,726</td>
</tr>
<tr>
<td><strong>SUPPLEMENTAL INFORMATION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest paid</td>
<td>$ 0</td>
<td>$ 0</td>
</tr>
<tr>
<td>Income taxes paid on unrelated business income</td>
<td>$ 0</td>
<td>$ 0</td>
</tr>
</tbody>
</table>

See Independent Auditor’s Report and Notes to the Financial Statements
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Nature of Activities
The United Mitochondrial Disease Foundation, Inc. (“the Foundation”) was organized on April 28, 1995, and is the result of a merger between a number of specific Mitochondrial disease organizations to form a larger, more cohesive united foundation representing all mitochondrial diseases and all sufferers, adult and children alike. The Foundation's mission is to promote research for cures and treatments of mitochondrial disorders and to provide support to affected families.

Basis of Accounting
The accompanying financial statements are prepared on the accrual basis of accounting, and accordingly, reflect all significant receivables, payables, and other liabilities.

Financial Statement Presentation
The Foundation's financial statements are prepared in accordance with FASB ASC 958-210 (formerly Statement of Financial Accounting Standards (SFAS) No. 117, “Financial Statements of Not-for-Profit Organizations”). Under FASB ASC 958-210, the Foundation is required to report information regarding its financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets and permanently restricted net assets.

Contributions
Contributions received are recorded as unrestricted or temporarily restricted net assets depending on the existence or nature of any donor restrictions.

Cash and Cash Equivalents
For purposes of the Statement of Cash Flows, the Foundation considers all highly liquid investments with an initial maturity of one year or less to be cash equivalents. For the years ended June 30, 2011 and 2010, the Foundation had no noncash investing or financing activities for cash flow purposes.

Estimates
Management uses estimates and assumptions in preparing financial statements. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported revenues and expenses. Actual results could differ from those estimates.

Inventories
Inventories consist of merchandise and are stated at the lower of cost (first-in-first-out) or market.

(Continued)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

**Investments**
The Foundation records investments in accordance with FASB ASC 958-320 (formerly SFAS No. 124, “Accounting for Certain Investments Held by Not-for-Profit Organizations”). Under FASB ASC 958-320, investments are presented at their fair value, which is established using the fair value hierarchy (See Note 3).

**Fixed Assets**
Fixed assets are recorded at cost and depreciated using the straight-line method over estimated useful lives of 5 to 7 years. Depreciation expense, totaling $34,186 and $59,071 for the years ended June 30, 2011 and 2010, respectively, is allocated to the various activities based on usage.

**Revenue and Expense Recognition**
Income from membership dues and program service fees are deferred and recognized over the periods to which the specific types of income relate. Costs and expenses related to such activities are also deferred as prepaid expenses and recognized in the period when the programs are held.

**Functional Allocation of Expenses**
The costs of providing the various programs and other activities have been summarized on a functional basis in the statement of activities and changes in net assets. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

**Income Tax Status**
The Foundation is exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code. However, income from certain activities not directly related to the Foundation’s tax-exempt purpose is subject to taxation as unrelated business income. For the years ended June 30, 2011 and 2010, the Foundation had no such income. In addition, the Foundation qualifies for the charitable contribution deduction under Section 170(b)(1)(A) and has been classified as an organization that is not a private foundation under Section 509(a)(1).

The Foundation adopted the accounting standard for uncertain tax positions as of July 1, 2009. The standard requires a two-step approach to recognizing and measuring uncertain tax positions accounted for in accordance with the asset and liability method. The first step is to evaluate the tax position for recognition by determining whether evidence indicates that it is more likely than not that a position will be sustained if examined by a taxing authority. The second step is to measure the tax benefit as the largest amount that is 50% likely of being realized upon settlement with a taxing authority. The adoption of this standard did not have a material impact on the Foundation’s financial statements.

The Forms 990, Return of Organization Exempt from Income Tax, of the Foundation are subject to examination by the IRS, generally for three years after they were filed.
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Concentration of Credit Risk
Financial instruments which potentially subject the organization to a concentration of credit risk consist principally of cash, temporary cash investments and marketable securities. The cash, temporary cash investments and marketable security accounts of the organization are maintained at high quality financial institutions. At times such accounts may be in excess of FDIC insurance limits, but pose no significant concentration of credit risk.

Changes in Presentation of Comparative Statements
Certain prior year amounts have been reclassified to conform to the current year presentation.

Subsequent Events
Management has evaluated subsequent events through January 6, 2012, the date on which the financial statements were available to be issued.

2. DESCRIPTION OF MAJOR PROGRAMS

Research
The Foundation is committed to finding treatments and cures for mitochondrial disease and believes research is the path to success. Since 1996 the Foundation has been providing research grants in order to advance the cause of research into mitochondrial disease.

Public Awareness
The Foundation is raising awareness among clinicians, pediatricians, general practitioners, and other allied health professionals through exhibition at annual medical meetings and its “Grand Rounds” lecture series at hospitals around the country. The Foundation has also produced “Mito 101” an interactive CD to educate primary care physicians and pediatricians about mitochondrial diseases and “MitoFirst” a handbook for newly diagnosed patients and their physicians.

Education/Member Support
The Foundation creates caring, supportive communities across the nation for adults, children and families suffering from mitochondrial disease through their local chapters and affiliated groups and ambassadors. This allows foundation members to network with other families and individuals to talk about mitochondrial disorders. The Foundation also keeps members updated with the latest treatment advances and information through a quarterly newsletter.

3. INVESTMENTS
Investments at June 30, 2011 are summarized as follows:

<table>
<thead>
<tr>
<th></th>
<th>Cost Basis</th>
<th>Gross Unrealized Gains</th>
<th>Gross Unrealized Losses</th>
<th>Fair Market Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutual funds</td>
<td>$1,214,653</td>
<td>$172,119</td>
<td>$0</td>
<td>$1,386,772</td>
</tr>
</tbody>
</table>

(Continued)
3. INVESTMENTS, Continued

Investments at June 30, 2010 are summarized as follows:

<table>
<thead>
<tr>
<th></th>
<th>Gross Cost</th>
<th>Unrealized Gains</th>
<th>Unrealized Losses</th>
<th>Fair Market Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutual funds</td>
<td>$1,176,348</td>
<td>$0</td>
<td>$(31,899)</td>
<td>$1,144,449</td>
</tr>
</tbody>
</table>

**Fair Value Measurements**

Generally accepted accounting principles (GAAP) establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy consists of three broad levels: Level 1 inputs consist of unadjusted quoted prices in active markets for identical assets and have the highest priority, Level 2 inputs consist of observable inputs other than quoted prices for identical assets, and Level 3 inputs have the lowest priority. The Company uses appropriate valuation techniques based on the available inputs to measure the fair value of its investments. When available, the Company measures fair value using Level 1 inputs because they generally provide the most reliable evidence of fair value. The fair values of the mutual funds are Level 1 inputs. No Level 2 or Level 3 inputs were available to the Company.

4. FIXED ASSETS

Fixed assets are summarized as follows at June 30:

<table>
<thead>
<tr>
<th>Fixed asset</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furniture and fixtures</td>
<td>$57,675</td>
<td>$57,675</td>
</tr>
<tr>
<td>Computer equipment</td>
<td>273,035</td>
<td>277,932</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>5,225</td>
<td>5,225</td>
</tr>
<tr>
<td><strong>Total fixed assets</strong></td>
<td>335,935</td>
<td>340,832</td>
</tr>
<tr>
<td><strong>Less accumulated depreciation</strong></td>
<td>295,803</td>
<td>277,661</td>
</tr>
<tr>
<td><strong>Fixed assets – net</strong></td>
<td><strong>$40,132</strong></td>
<td><strong>$63,171</strong></td>
</tr>
</tbody>
</table>

5. GRANTS PAYABLE

Grants authorized but unpaid at year end are reported as liabilities in accordance with FASB ASC 958-605 (formerly SFAS No. 116, “Accounting for Contributions Received and Contributions Made”).

In May 2005, the Board of Trustees approved future research grants totaling $1,018,489 to be paid to qualified recipients from the years 2005 through 2007. During the year ended June 30, 2011, $519 of these grants were cancelled. As of June 30, 2011, there were no amounts unpaid.

In May 2006, the Board of Trustees approved future research grants totaling $1,025,021 to be paid to qualified recipients from the years 2006 through 2008. During the year ended June 30, 2011 $36,315 of these grants were cancelled. As of June 30, 2011, $11,400 was unpaid.

(Continued)
5. GRANTS PAYABLE, Continued

In May 2007, the Board of Trustees approved future research grants totaling $1,150,637 to be paid to qualified recipients from the years 2007 through 2009. During the year ended June 30, 2011, $683 of these grants were cancelled. As of June 30, 2011, there were no amounts unpaid.

In May 2008, the Board of Trustees approved future research grants totaling $1,025,080 to be paid to qualified recipients from the years 2008 through 2010. During the year ended June 30, 2011, $5,983 of these grants were cancelled. As of June 30, 2011, there were no amounts unpaid.

In May 2009, the Board of Trustees approved future research grants totaling $412,661 to be paid to qualified recipients from the years 2009 through 2011. As of June 30, 2011, $70,395 was unpaid.

In May 2010, the Board of Trustees approved future research grants totaling $315,348 to be paid to qualified recipients from the years 2010 through 2012. As of June 30, 2011 $127,674 was unpaid.

In May 2011, the Board of Trustees approved future research grants totaling $640,000 to be paid to qualified recipients from the years 2011 through 2013. As of June 30, 2011, all grants awarded in the current fiscal year were unpaid.

6. RETIREMENT PLANS

**403(b) Tax Deferred Annuity Plan**
The Company has a 403(b) Tax Deferred Annuity Plan covering substantially all of its employees. Employees may make voluntary pre-tax contributions to the plan subject to maximums allowed by the Internal Revenue Code. The Company does not match any of the contributions.

**SEP-IRA Plan**
The Company also has established a SEP-IRA retirement plan for substantially all employees. Contributions are determined by management and are totally discretionary. Contributions amounted to approximately $28,000 and $21,000 for the years ended June 30, 2011 and 2010, respectively.

7. NET ASSETS
Temporarily restricted net assets at June 30, 2011 and 2010 are available for the following purposes:

<table>
<thead>
<tr>
<th>Purpose</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$322,527</td>
<td>$267,609</td>
</tr>
</tbody>
</table>

(Continued)
8. OPERATING LEASE
The Foundation leases office space under an operating lease agreement that expires October 2012. The Foundation leases a copier under an operating lease agreement that expires November 2011. The Foundation also leases a postage machine under an operating lease agreement that expires June 2014. The future minimum rental payments required under these lease agreements are:

<table>
<thead>
<tr>
<th>Year Ended</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 30, 2012</td>
<td>$65,980</td>
</tr>
<tr>
<td>2013</td>
<td>18,462</td>
</tr>
<tr>
<td>2014</td>
<td>2,280</td>
</tr>
<tr>
<td>Thereafter</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>$86,722</td>
</tr>
</tbody>
</table>

Rental expense amounted to $67,033 and $60,634 for the years ended June 30, 2011 and 2010, respectively.

9. CONTRIBUTED SERVICES
FASB ASC 958-605 requires contributed services to be recognized if the services received create or enhance nonfinancial assets or require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by volunteers. The Foundation receives such services from community members who volunteer to provide video production, website development and accounting services. The value of these services was calculated as $33,605 and $39,222 for the years ended June 30, 2011 and 2010, respectively, and is included in the accompanying Statements of Activities as revenue and expense.

10. CHAPTERS
In addition to the national office of the United Mitochondrial Disease Foundation, Inc., local chapters have also been formed throughout the United States. These chapters include:

Ohio Chapter
Delaware Valley Chapter
Southern California Chapter
Kansas City Chapter
New England Chapter
Arizona Chapter
New York Metro Chapter
Indiana Chapter
Atlanta Chapter
Chicago Chapter
Houston Chapter
Central Ohio Chapter
Carolina Foothills Chapter
Minneapolis-St. Paul Chapter
Middle Tennessee Chapter
D/C/Baltimore/Northern Virginia Chapter

(Continued)
10. CHAPTERS, Continued

Each chapter is required to file an application for their own employer identification number, abide by their signed chapter affiliation agreement and by-laws and to provide the national office their monthly chapter finance report. The Foundation has received a group exemption under 501(c)(3) of the Internal Revenue Code, and accordingly, will file a group tax return for the chapters. The primary purpose of the chapters is to provide a support network and conduct charitable fundraising activities for the Foundation. The chapters meet the requirements for consolidation and accordingly, their balances are included in the accompanying financial statements.

The Statements of Financial Condition include the cash balances of each chapter as of June 30 as follows:

<table>
<thead>
<tr>
<th>Chapter</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ohio Chapter</td>
<td>$4,496</td>
<td>$32,449</td>
</tr>
<tr>
<td>Delaware Valley Chapter</td>
<td>209</td>
<td>1,080</td>
</tr>
<tr>
<td>Kansas City Chapter</td>
<td>5,663</td>
<td>1,963</td>
</tr>
<tr>
<td>New England Chapter</td>
<td>1,000</td>
<td>1,000</td>
</tr>
<tr>
<td>Indiana Chapter</td>
<td>6,619</td>
<td>6,616</td>
</tr>
<tr>
<td>Atlanta Chapter</td>
<td>1,078</td>
<td>1,994</td>
</tr>
<tr>
<td>Chicago Chapter</td>
<td>1,397</td>
<td>1,399</td>
</tr>
<tr>
<td>Houston Chapter</td>
<td>13,772</td>
<td>17,122</td>
</tr>
<tr>
<td>Carolina Foothills Chapter</td>
<td>5,362</td>
<td>3,536</td>
</tr>
<tr>
<td>Minneapolis-St. Paul Chapter</td>
<td>6,606</td>
<td>4,296</td>
</tr>
<tr>
<td>Central Ohio Chapter</td>
<td>0</td>
<td>1,326</td>
</tr>
<tr>
<td>Middle Tennessee Chapter</td>
<td>1,654</td>
<td>693</td>
</tr>
<tr>
<td>D/C/Baltimore/Northern Virginia Chapter</td>
<td>7,728</td>
<td>7,339</td>
</tr>
</tbody>
</table>
10. CHAPTERS, Continued

The Statements of Activities and Changes in Net Assets for the years ended June 30, 2011 and 2010 includes the activity for each chapter as follows:

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Revenue 2011</th>
<th>Expenses 2011</th>
<th>Revenue 2010</th>
<th>Expenses 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ohio Chapter</td>
<td>$132,575</td>
<td>$15,146</td>
<td>$135,838</td>
<td>$24,824</td>
</tr>
<tr>
<td>New England Chapter</td>
<td>10,583</td>
<td>3,655</td>
<td>65,182</td>
<td>9,001</td>
</tr>
<tr>
<td>Southern California Chapter</td>
<td>6,483</td>
<td>2,393</td>
<td>22,045</td>
<td>5,970</td>
</tr>
<tr>
<td>Delaware Valley Chapter</td>
<td>46,855</td>
<td>8,202</td>
<td>120,647</td>
<td>30,841</td>
</tr>
<tr>
<td>Arizona Chapter</td>
<td>61,189</td>
<td>5,351</td>
<td>980</td>
<td>43</td>
</tr>
<tr>
<td>New York Metro Chapter</td>
<td>10,055</td>
<td>4,724</td>
<td>21,493</td>
<td>5,317</td>
</tr>
<tr>
<td>Kansas City Chapter</td>
<td>30,741</td>
<td>3,555</td>
<td>14,354</td>
<td>1,051</td>
</tr>
<tr>
<td>Indiana Chapter</td>
<td>54,587</td>
<td>8,624</td>
<td>30,984</td>
<td>5,530</td>
</tr>
<tr>
<td>Atlanta Chapter</td>
<td>153,392</td>
<td>37,449</td>
<td>188,955</td>
<td>65,978</td>
</tr>
<tr>
<td>Chicago Chapter</td>
<td>71,880</td>
<td>15,464</td>
<td>51,994</td>
<td>8,237</td>
</tr>
<tr>
<td>Houston Chapter</td>
<td>197,507</td>
<td>45,820</td>
<td>117,517</td>
<td>25,380</td>
</tr>
<tr>
<td>Central Ohio Chapter</td>
<td>4,715</td>
<td>7</td>
<td>39,481</td>
<td>18,571</td>
</tr>
<tr>
<td>Carolina Foothills Chapter</td>
<td>95,033</td>
<td>10,874</td>
<td>24,642</td>
<td>690</td>
</tr>
<tr>
<td>Minneapolis-St. Paul Chapter</td>
<td>70,482</td>
<td>7,554</td>
<td>51,017</td>
<td>6,962</td>
</tr>
<tr>
<td>Middle Tennessee Chapter</td>
<td>83,703</td>
<td>12,660</td>
<td>32,940</td>
<td>5,372</td>
</tr>
<tr>
<td>D/C/Baltimore/Northern</td>
<td>40,983</td>
<td>21,810</td>
<td>39,460</td>
<td>13,394</td>
</tr>
<tr>
<td>Total</td>
<td>$1,070,763</td>
<td>$203,288</td>
<td>$957,529</td>
<td>$227,161</td>
</tr>
</tbody>
</table>

(Concluded)
UMDF National Office Staff

Charles A. Mohan Jr., CEO/Executive Director
Mark Campbell, Chief Financial Officer
Kara Strittmatter, Director of Member Services
Clifford Gorski, Director of Communications
Marian Weil, Director of Development
Tania Hanscom, Special Events Coordinator
Scott Precopia, IT Manager
Jean Bassett, Research Grants Coordinator
Alison Cooley, Communications Assistant
Don Gielas, Grant Writer
Justin Lantz, IT Multimedia Associate
Rachel Mazur, Special Events Associate
Donna Nameth, Data Entry Manager
Melinda O’Toole, Member Services Associate
Janet Owens, Executive Administrative Assistant
Barbara Podowski, Administrative Assistant
Nicole Shanter, Special Events Associate

UMDF MISSION
To promote research and education for the diagnosis, treatment, and cure of mitochondrial disorders and to provide support to affected individuals and families.
UMDF Scientific and Medical Advisory Board

Carlos Moraes, PhD - Chairman
University of Miami
Miami, FL

Russell Saneto, DO, PhD - Secretary
Seattle Children’s
Seattle, WA

Laurence Bindoff, MD
Haukeland University Hospital
Bergen, Norway

Rod Capaldi, PhD
University of Oregon
Eugene, OR

David Chan, PhD
California Institute of Technology
Pasadena, CA

Patrick Chinnery, PhD, MRCP
University of Newcastle upon Tyne
Newcastle upon Tyne, UK

William Copeland, PhD
National Institute of Environmental Health Sciences (NIEH)
Research Triangle Park, NC

Greg Enns, MB, ChB
Stanford University
Stanford, CA

Michio Hirano, MD
Columbia University Medical Center
New York, NY

Edward McKee, PhD
Indiana University School of Medicine
South Bend, IN

Vamsi Mootha, MD
Harvard Medical School
Boston, MA

Fernando Scaglia, MD
Baylor College of Medicine
Houston, TX

Peter Stacpoole, PhD, MD
University of Florida
Gainesville, FL

Mark Tarnopolsky, MD, PhD, FRCP(C)
McMaster University
Hamilton, Ontario, Canada

Massimo Zeviani, MD
National Neurological Institute C. Besta
Milano, Italy
$\textbf{UMDF Board of Trustees}$

Dan Wright  
Chairman  
Dallas, TX

Sharon Shaw  
Vice Chairman  
Scottsdale, AZ

Marty Lyman  
Secretary  
Cuyahoga Falls, OH

Richard Kubach  
Treasurer  
King of Prussia, PA

Chuck Mohan  
Chair Emeritus  
Pittsburgh, PA

Bruce Cohen, MD  
Trustee  
Akron, OH

Gerald Cook, Esq.  
Trustee  
Pittsburgh, PA

Linda Cooper  
Trustee  
Orange, CA

John DiCecco  
Treasurer  
Westerville, OH

Amy Goldstein, MD  
Trustee  
Pittsburgh, PA
UMDF Board of Trustees

Leslie Boyer Heilman, JD
Trustee
Pittsburgh, PA

Richard Leach
Trustee
Washington, D.C.

Molly Auth Manning
Trustee
Boston, MA

Carlos Moraes, PhD
Trustee
Miami, FL

Tyler Reimschisel, MD
Trustee
Nashville, TN

Joseph Rice
Trustee
Mount Juliet, TN

Philip Yeske, PhD
Trustee
Pittsburgh, PA

Darcy Zehe
Chapter Liaison
Cleveland, OH

Howard Zucker, JD, MD
Trustee
Cliffside Park, NJ
UMDF Chapters, Mito Groups, and Ambassadors

To reach an Ambassador, simply e-mail ambassadors@umdf.org. When sending the e-mail, please include the leader’s name or city/state in the subject line for us to better serve your needs.

★ Stars Denote Chapters

ALABAMA
North Alabama Mito Group
Contact: Margie Slemp, Huntsville

ARIZONA
Ambassador:
Contact: Gina Blair, Peoria

ARKANSAS
Ambassador:
Lacie Moore, Rogers

CALIFORNIA
★California Chapter
President: Norma Gibson
E-mail: CalChapter@umdf.org
Ambassador:
Cheryl Burge, Beaumont

DELAWARE
Ambassador:
Contact: Judy Weeks, Dover

FLORIDA
Central Florida Mito Group
Contact: Amber Ferrell, Gainsville
Contact: Jennifer Slauder, Orlando
Ambassadors:
Sophie Szilagy, North East Florida
Holly Schneider, Coconut Creek

GEORGIA
★Atlanta Area Chapter
President: Chris Swinn
E-mail: ATLchapter@umdf.org
Atlanta Chapter Support
Contact: Shelly Lorenzen, Sugar Hill

Ambassadors:
Hannah Bossie, Athens
Gail LaFramboise, West Central Georgia

HAWAII
Ambassador:
Kimo Phan, Honolulu

IDAHO
Idaho Mito Group
Contact: Jennifer Pfefferle, Boise

INDIANA
★Indiana Chapter
President: Jackie Parrish
E-mail: INchapter@umdf.org

AMBASSADORS:
Luke or Leslie Kirby, Philo
Patti Bauer, Springfield
St. Louis Area Mito Group
Contacts: Hope Grover, Victoria Helms, & Keli Stone

IOWA
Iowa Mito Group
Contacts: Kim Novy, Des Moines
Darla Klein, Des Moines
Ambassador:
Ronda Eick, Northern Iowa

LOUISIANA
Ambassadors:
Mandy Poche, Baton Rouge
Anna Stewart, Bossier City
Chantel Wodey, Corinton

MAINE
Ambassador:
Amber Taylor, Bangor

MARYLAND
★DC / Baltimore / Northern Virginia Chapter
President: Sharon Goldin
E-mail: dcbaltimore@umdf.org

MASSACHUSETTS/CONNECTICUT
New England Mito Group
Contact: National Office

MICHIGAN
Michigan Mito Group
Contact: Julie Scott, Novi
Ambassadors:
Carrie Gervasone, Fraser
Holly Worden, Lakeview

MINNESOTA
★Minneapolis/St. Paul Chapter
President: Kalynn Wendt
E-mail: MNChapter@umdf.org

MISSISSIPPI
Greater Jackson Mito Group
Contact: Julie Manley, Jackson

MISSOURI / KANSAS
Kansas City Mito Group
Contact: Theresa Edwards, Kansas City
St. Louis Area Mito Group
Contacts: Hope Grover, Victoria Helms, & Keli Stone

NEW MEXICO
Ambassador:
Stephanie Cassady, Albuquerque
UMDF Chapters, Mito Groups, and Ambassadors

**NEW YORK**
★ New York Metro Chapter  
President: Kim Zuzzolo  
E-mail: NYMetroChapter@umdf.org  
Western New York Mito Group  
Contacts: Linda Roesch, Buffalo  
Jennifer Schwartzoff, Buffalo  
Ambassadors:  
Jacqueline Perrotta, Albany  
Lori Piccirilli, Binghamton  
Kimberly Dedrick, Utica

**NORTH CAROLINA**
★ Tar Heel Mito Group  
Contacts: Heather Baudet, Raleigh Durham  
Adriana Smith, Raleigh Durham  
Ambassadors:  
Terry Holeman, Fayetteville  
Jenny Hobb, Winston-Salem

**OHIO**
★ Ohio Chapter – North East  
President: Darcy Zehe  
E-mail: OHChapter@umdf.org  
Central Ohio Mito Group  
Contacts: Ruth Gerke & Jody Thompson

**OREGON**
Ambassador: Kimberli Freilinger, Monmouth

**Pennsylvania**
★ Delaware Valley Chapter  
Contact: Laurel Smith  
E-mail: DelValChapter@umdf.org  
Erie Mito Group  
Contact: Jessica Myers  
Pittsburgh Mito Group  
Contact: Kimberly Dojonovic  
Ambassadors:  
Kim Olenderski, Central Pennsylvania  
Daria Grabowski, Erie  
Karen Wilson, Pittsburgh (adults)  
Heather Pallas, Pittsburgh (children)

**SOUTH CAROLINA**
★ Carolina Foothills Chapter  
Contacts: Christy Koury & Margaret Moore  
E-mail: carolinafoothills@umdf.org  
Ambassador  
Karis Mott, Chapin

**TENNESSEE**
★ Middle Tennessee Chapter  
President: Courtney Fellers  
E-mail: midtennchapter@umdf.org  
Memphis Area Mito Group  
Contact: Emily Culley & Karrie LaCroix

**TEXAS**
★ Houston Chapter  
President: Deb Schindler-Boultinghouse  
E-mail: HoustonChapter@umdf.org  
North Texas Mito Group  
Contact: Joshua Brewer  
Ambassador:  
Shamayn Kennedy, Wichita Falls

**UTAH**
Ambassador:  
Laura McCluskey, Orem

**VERMONT**
Ambassador:  
MaryBeth LeFevre, Vermont

**VIRGINIA**
Ambassadors:  
Heather Meyer, Lynchburg  
Molly McCaffrey Adams, Richmond

**WASHINGTON**
Ambassador:  
Joy Krumdiack, NW Washington

**WISCONSIN**
Ambassadors:  
Jaqueline Bohne, Harshaw  
Mindy Welhouse, Kimberly  
Terilyn Musser, LaCrosse/Eau Claire  
Karen Loftus, Milwaukee

**INTERNATIONAL**
Ambassadors:  
Rob Ryan, Australia  
John Carreiro, British Columbia  
Nilam Argawal, India  
Saijad Haider, Pakistan  
Anne Hansen, Norway  
Vidar Hunstad Vik, Norway  
Rowland Dicker, United Kingdom  
Keely Schellenberg, Winnipeg

**YOUTH AMBASSADORS**
Joe Wise, California  
Emily Swinn, Georgia  
Briana Garrido, Hawaii  
Haley Wroth, Massachusetts/Connecticut  
Alexandra Simonian, New York  
Tyler Liebegott, Pennsylvania  
Colleen Powell, Pennsylvania  
Devin Shuman, Washington
UNITED MITOCHONDRIAL DISEASE FOUNDATION.

HOPE. ENERGY. LIFE.

8085 Saltsburg Rd., Suite 201
Pittsburgh, PA 15239
Phone: 1.888.317.UMDF (toll free)
Phone: 412.793.8077
Fax: 412.793.6477
info@umdf.org
www.umdf.org